Pluri (PLUR) Income from Continuing Operations (2010 - 2025)
Pluri (PLUR) reported Income from Continuing Operations of 6872000.0 for Q4 2025, down 120.96% year-over-year from 32779018.4 in Q4 2024, and down 12.07% quarter-over-quarter from 6132000.0 in Q3 2025.
Pluri (PLUR) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Pluri (PLUR) has 16 years of Income from Continuing Operations data on file, last reported at 6872000.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 6872000.0, down 120.96% year-over-year; the trailing twelve-month figure through Dec 2025 was 25470000.0 (down 20.43% YoY), and the FY2025 annual result was 23250000.0, down 8.93% from the prior year.
- Income from Continuing Operations eased to 6872000.0 in Q4 2025 per PLUR's latest filing, from 6132000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3110000.0 in Q4 2024 and troughed at 14587000.0 in Q2 2021.
- A 5-year average of 7806700.0 and a median of 6863000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 42.72% in 2024, then tumbled 120.96% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 10795000.0 in 2021, then surged by 36.16% to 6891000.0 in 2022, then gained by 21.22% to 5429000.0 in 2023, then jumped by 42.72% to 3110000.0 in 2024, then tumbled by 120.96% to 6872000.0 in 2025.
- Business Quant data shows PLUR's Income from Continuing Operations at 6872000.0 in Q4 2025, 6132000.0 in Q3 2025, and 6854000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | -6.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.87 Mn |
| Sep 30, 2025 | -6.13 Mn |
| Jun 30, 2025 | -6.85 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Jun 30, 2024 | -6.25 Mn |
| Mar 31, 2024 | -5.75 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | -5.59 Mn |
| Jun 30, 2023 | -6.76 Mn |
| Mar 31, 2023 | -7.32 Mn |
| Dec 31, 2022 | -6.89 Mn |
| Sep 30, 2022 | -7.12 Mn |
| Jun 30, 2022 | -8.88 Mn |
| Mar 31, 2022 | -10.48 Mn |
| Dec 31, 2021 | -10.80 Mn |
| Sep 30, 2021 | -11.44 Mn |
| Jun 30, 2021 | -14.59 Mn |
| Mar 31, 2021 | -14.23 Mn |